<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PIPERACILLIN AND TAZOBACTAM- piperacillin sodium and tazobactam sodium injection, powder, for solution </strong><br>Fresenius Kabi USA, LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use Piperacillin and Tazobactam for Injection safely and effectively. See full prescribing information for Piperacillin and Tazobactam for Injection.<br><br>Piperacillin and Tazobactam for Injection: pharmacy bulk package bottles<br>Initial U.S. Approval: 1993<br>To reduce the development of drug-resistant bacteria and maintain the effectiveness of Piperacillin and Tazobactam for Injection and other antibacterial drugs, Piperacillin and Tazobactam for Injection should be used only to treat <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">Piperacillin and Tazobactam for Injection is a combination penicillin-class antibacterial and β-lactamase inhibitor indicated for treatment of:  </p>
<dl>
<dt>•</dt>
<dd>Intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">abdominal infections</span> (<a href="#LINK_4d23b23b-075d-47b0-b10a-aae32bfe798f">1.1</a>)</dd>
<dt>•</dt>
<dd>Skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (<a href="#LINK_d7e1adfb-c4be-462b-a7ba-d654e53c5316">1.2</a>)</dd>
<dt>•</dt>
<dd>Female <span class="product-label-link" type="condition" conceptid="4003306" conceptname="Infection of pelvis">pelvic infections</span> (<a href="#LINK_6baecf9f-77e3-4e26-a4ca-d7d7fa6334a2">1.3</a>)</dd>
<dt>•</dt>
<dd>Community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (<a href="#LINK_71c49755-a487-455c-ab53-b9b5451a0891">1.4</a>)</dd>
<dt>•</dt>
<dd><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Nosocomial pneumonia</span> (<a href="#LINK_1a8dffba-6769-408c-8226-e6499e428044">1.5</a>)</dd>
</dl>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>•</dt>
<dd>The usual daily dose of Piperacillin and Tazobactam for Injection for adults is 3.375 g every six hours totaling 13.5 g (12.0 g piperacillin/1.5 g tazobactam) (<a href="#LINK_e33bcafe-5745-4b0c-8fd4-4df66295ec9f">2.1</a>) </dd>
<dt>•</dt>
<dd>Initial presumptive treatment of patients with <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">nosocomial pneumonia</span> should start with Piperacillin and Tazobactam for Injection at a dosage of 4.5 g every six hours plus an aminoglycoside, totaling 18.0 g (16.0 g piperacillin/2.0 g tazobactam). (<a href="#LINK_5ad0268b-3264-4d79-a540-ebc31f6c7613">2.2</a>) </dd>
<dt>•</dt>
<dd>Dosage in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (≤40 mL/min of CRCL) and dialysis patients should be reduced, based on the degree of actual renal function impairment. (<a href="#LINK_11248975-57b2-4e67-b340-4d88270ba15d">2.3</a>) </dd>
<dt>•</dt>
<dd>For children with <span class="product-label-link" type="condition" conceptid="440448" conceptname="Appendicitis">appendicitis</span> and/or <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span> the recommended Piperacillin and Tazobactam for Injection dosage is 100 mg piperacillin/12.5 mg tazobactam per kilogram of body weight, every 8 hours in pediatric patients 9 months of age and older. For pediatric patients 2 to 9 months of age, the recommended dosage is 80 mg piperacillin/10 mg tazobactam per kilogram of body weight, every 8 hours. (<a href="#LINK_72092c0e-4d2b-42da-aec2-4d54e9e8e614">2.4</a>) </dd>
<dt>•</dt>
<dd>Piperacillin and Tazobactam for Injection and aminoglycosides should be reconstituted, diluted, and administered separately. Co-administration via Y-site can be done under certain conditions. (<a href="#LINK_2cb5da21-3f04-43ca-ad17-850b38624dd1">2.6</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Piperacillin and Tazobactam for Injection: 40.5 g lyophilized powder for reconstitution in pharmacy bulk package bottles (<a href="#LINK_abff6fc2-20a6-4b2f-b135-e774b8c3eef2">3</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to any of the penicillins, cephalosporins, or β-lactamase inhibitors. (<a href="#LINK_d6471d7a-111b-48df-af25-62107057cb64">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> (anaphylactic/anaphylactoid) reactions have been reported in patients receiving Piperacillin and Tazobactam for Injection.  Discontinue Piperacillin and Tazobactam for Injection if a reaction occurs. (<a href="#LINK_9554029a-f177-4048-a5e1-ebd502477458">5.1</a>) </dd>
<dt>•</dt>
<dd>Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, such as <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, have been reported (<a href="#LINK_7dd610ac-dcf2-445d-9af7-63ca3343d0a2">5.2</a>). Discontinue Piperacillin and Tazobactam for Injection for progressive <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rashes</span>. </dd>
<dt>•</dt>
<dd>
<span class="Italics">Clostridium difficile </span>associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>: evaluate patients if <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs. (<a href="#LINK_ea08149e-db44-469e-8d62-9499dba29914">5.3</a>) </dd>
<dt>•</dt>
<dd>Hematological effects (including <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>) have occurred. Monitor hematologic tests during prolonged therapy. (<a href="#LINK_876b1068-1aa3-4811-84a7-542813a2ec9c">5.4</a>) </dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common adverse reactions (incidence &gt;5%) are <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span> and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>. (<a href="#LINK_d36cb5fd-0847-4c97-ae7d-546c6c482a88">6.1</a>)  </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC Vigilance and Medical Affairs at 1-800-551-7176 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. </span> </p>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>•</dt>
<dd>Piperacillin and Tazobactam for Injection administration can significantly reduce tobramycin concentrations in hemodialysis patients. Monitor tobramycin concentrations in these patients. (<a href="#LINK_2f9dbd2c-9dc0-4480-891f-444e50c34ea7">7.1</a>) </dd>
<dt>•</dt>
<dd>Probenecid prolongs the half-lives of piperacillin and tazobactam and should not be co-administered with Piperacillin and Tazobactam for Injection unless the benefit outweighs the risk. (<a href="#LINK_8e4d6a5e-7693-4f2d-bc83-0f0344282aea">7.2</a>) </dd>
<dt>•</dt>
<dd>Monitor coagulation parameters in patients receiving Piperacillin and Tazobactam for Injection and heparin or oral anticoagulants. (<a href="#LINK_a47a8645-d911-4034-987c-53ca313b5577">7.3</a>) </dd>
<dt>•</dt>
<dd>Piperacillin and Tazobactam for Injection may prolong the <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> of vecuronium and other non-depolarizing muscle relaxants. Monitor for adverse reactions related to <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span>. (<a href="#LINK_f32a7553-066c-4cfc-a468-ec9029aa9f21">7.4</a>) </dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><p class="Highlighta">Dosage in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (≤40 mL/min of CRCL) should be reduced to the degree of actual renal function impairment. (<a href="#LINK_11248975-57b2-4e67-b340-4d88270ba15d">2.3</a>, <a href="#LINK_a03893ac-ef43-4867-aacd-20493e352c54">8.6</a>) </p></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 6/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">abdominal Infections</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2 Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></a></h2>
<h2><a href="#section-1.3" class="toc">1.3 Female <span class="product-label-link" type="condition" conceptid="4003306" conceptname="Infection of pelvis">Pelvic Infections</span></a></h2>
<h2><a href="#section-1.4" class="toc">1.4 Community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></a></h2>
<h2><a href="#section-1.5" class="toc">1.5 <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Nosocomial Pneumonia</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Adult Patients</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Nosocomial Pneumonia</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Pediatric Patients</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Reconstitution and Dilution of Powder Formulations</a></h2>
<h2><a href="#section-2.6" class="toc">2.6 Compatibility with Aminoglycosides</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2 Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 <span class="Italics">Clostridium difficile</span> Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Hematologic Effects</a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Central Nervous System Effects</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 Electrolyte Effects</a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Development of Drug-Resistant Bacteria</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Post-Marketing Experience</a></h2>
<h2><a href="#section-6.3" class="toc">6.3 Additional Experience with piperacillin</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Aminoglycosides</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Probenecid</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Anticoagulants</a></h2>
<h2><a href="#section-7.4" class="toc">7.4 Vecuronium</a></h2>
<h2><a href="#section-7.5" class="toc">7.5 Methotrexate</a></h2>
<h2><a href="#section-7.6" class="toc">7.6 Effects on Laboratory Tests</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.4" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.6" class="toc">8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.8 Patients with <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">Cystic Fibrosis</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h2><a href="#section-11.4" class="toc">12.4 Microbiology</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">15 REFERENCES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="ID_8b055e5c-92ff-43f8-a987-2abad3f99c73"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PHARMACY BULK PACKAGE – NOT FOR DIRECT INFUSION</span></p>
<p>Reconstituted stock solution must be transferred and further diluted for IV infusion</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_4c484783-2f41-4aff-bb25-60e1b183742c"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Piperacillin and tazobactam for injection is a combination product consisting of a penicillin-class antibacterial, piperacillin, and a β-lactamase inhibitor, tazobactam, indicated for the treatment of patients with moderate to severe <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible isolates of the designated bacteria in the conditions listed below.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4d23b23b-075d-47b0-b10a-aae32bfe798f"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">abdominal Infections</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="440448" conceptname="Appendicitis">Appendicitis</span> (complicated by rupture or <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span>) and <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span> caused by β-lactamase producing isolates of <span class="Italics">Escherichia coli </span>or the following members of the <span class="Italics">Bacteroides fragilis </span>group: <span class="Italics">B. fragilis</span>, <span class="Italics">B. ovatus</span>, <span class="Italics">B. thetaiotaomicron</span>, or <span class="Italics">B. vulgatus</span>. The individual members of this group were studied in fewer than 10 cases.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d7e1adfb-c4be-462b-a7ba-d654e53c5316"></a><a name="section-1.2"></a><p></p>
<h2>1.2 Skin and Skin Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span></h2>
<p class="First">Uncomplicated and complicated skin and skin structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, including <span class="product-label-link" type="condition" conceptid="435613" conceptname="Cellulitis">cellulitis</span>, cutaneous <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscesses</span> and ischemic/<span class="product-label-link" type="condition" conceptid="4087682" conceptname="Diabetic foot">diabetic foot</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by β-lactamase producing isolates of <span class="Italics">Staphylococcus aureus</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6baecf9f-77e3-4e26-a4ca-d7d7fa6334a2"></a><a name="section-1.3"></a><p></p>
<h2>1.3 Female <span class="product-label-link" type="condition" conceptid="4003306" conceptname="Infection of pelvis">Pelvic Infections</span></h2>
<p class="First">Postpartum <span class="product-label-link" type="condition" conceptid="4302765" conceptname="Endometritis">endometritis</span> or <span class="product-label-link" type="condition" conceptid="199067" conceptname="Inflammatory disease of female pelvic organs AND/OR tissues">pelvic inflammatory disease</span> caused by β-lactamase producing isolates of <span class="Italics">Escherichia coli</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_71c49755-a487-455c-ab53-b9b5451a0891"></a><a name="section-1.4"></a><p></p>
<h2>1.4 Community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></h2>
<p class="First">Community-acquired <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span> (moderate severity only) caused by β-lactamase producing isolates of <span class="Italics">Haemophilus influenzae</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_1a8dffba-6769-408c-8226-e6499e428044"></a><a name="section-1.5"></a><p></p>
<h2>1.5 <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Nosocomial Pneumonia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Nosocomial pneumonia</span> (moderate to severe) caused by β-lactamase producing isolates of <span class="Italics">Staphylococcus aureus </span>and by piperacillin/tazobactam-susceptible <span class="Italics">Acinetobacter baumannii</span>, <span class="Italics">Haemophilus influenzae</span>, <span class="Italics">Klebsiella pneumoniae</span>, and <span class="Italics">Pseudomonas aeruginosa </span>(<span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Nosocomial pneumonia</span> caused by <span class="Italics">P. aeruginosa </span>should be treated in combination with an aminoglycoside) [<span class="Italics">see Dosage and Administration (<a href="#LINK_1803439c-d626-4421-ae9c-cd667a0cf47e">2</a>)</span>].</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.  When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.  In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_1803439c-d626-4421-ae9c-cd667a0cf47e"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First">Piperacillin and tazobactam for injection should be administered by intravenous infusion over 30 minutes.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e33bcafe-5745-4b0c-8fd4-4df66295ec9f"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Adult Patients</h2>
<p class="First">The usual total daily dose of piperacillin and tazobactam for injection for adults is 3.375 g every six hours totaling 13.5 g (12.0 g piperacillin/1.5 g tazobactam).  The usual duration of piperacillin and tazobactam for injection treatment is from 7 to 10 days.</p>
<p>Piperacillin and tazobactam for injection should be administered by intravenous infusion over 30 minutes. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_5ad0268b-3264-4d79-a540-ebc31f6c7613"></a><a name="section-2.2"></a><p></p>
<h2>2.2 <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Nosocomial Pneumonia</span></h2>
<p class="First">Initial presumptive treatment of patients with <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">nosocomial pneumonia</span> should start with piperacillin and tazobactam for injection at a dosage of 4.5 g every six hours plus an aminoglycoside, totaling 18.0 g (16.0 g piperacillin/2.0 g tazobactam).  The recommended duration of piperacillin and tazobactam for injection treatment for <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">nosocomial pneumonia</span> is 7 to 14 days.  Treatment with the aminoglycoside should be continued in patients from whom <span class="Italics">P. aeruginosa </span>is isolated. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_11248975-57b2-4e67-b340-4d88270ba15d"></a><a name="section-2.3"></a><p></p>
<h2>2.3 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">In patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (creatinine clearance ≤ 40 mL/min) and dialysis patients (hemodialysis and CAPD), the intravenous dose of piperacillin and tazobactam for injection should be reduced to the degree of actual renal function impairment.  The recommended daily doses of piperacillin and tazobactam for injection for patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> are as follows:</p>
<table width="100%">
<col width="34%">
<col width="44%">
<col width="21%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Toprule" align="center" colspan="3"><p class="First"><span class="Bold">Table 1:  Recommended Dosing of Piperacillin and Tazobactam for Injection in Patients with Normal Renal Function and <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> (As total grams piperacillin/tazobactam)</span></p></td></tr>
<tr>
<td align="center"><p class="First"><span class="Bold">Renal Function</span></p></td>
<td align="center"><p class="First"><span class="Bold">    </span></p></td>
<td align="center"><p class="First"><span class="Bold">      </span></p></td>
</tr>
<tr>
<td align="center"><p class="First"><span class="Bold">(creatinine clearance,</span></p></td>
<td align="center"><p class="First"><span class="Bold">All Indications</span></p></td>
<td align="center"><p class="First"><span class="Bold">Nosocomial</span></p></td>
</tr>
<tr>
<td class="Botrule" align="center"><p class="First"><span class="Bold">mL/min)</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold">(except <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">nosocomial pneumonia</span>)</span></p></td>
<td class="Botrule" align="center"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></span></p></td>
</tr>
<tr>
<td align="center"><p class="First">&gt;40 mL/min</p></td>
<td align="center"><p class="First">3.375 q6h</p></td>
<td align="center"><p class="First">4.5 q6h</p></td>
</tr>
<tr>
<td align="center"><p class="First">20-40 mL/min*</p></td>
<td align="center"><p class="First">2.25 q6h</p></td>
<td align="center"><p class="First">3.375 q6h</p></td>
</tr>
<tr>
<td align="center"><p class="First">&lt;20 mL/min*</p></td>
<td align="center"><p class="First">2.25 q8h</p></td>
<td align="center"><p class="First">2.25 q6h</p></td>
</tr>
<tr>
<td align="center"><p class="First">Hemodialysis**</p></td>
<td align="center"><p class="First">2.25 q12h</p></td>
<td align="center"><p class="First">2.25 q8h</p></td>
</tr>
<tr>
<td class="Botrule" align="center"><p class="First">CAPD</p></td>
<td class="Botrule" align="center"><p class="First">2.25 q12h</p></td>
<td class="Botrule" align="center"><p class="First">2.25 q8h</p></td>
</tr>
<tr class="Last"><td class="Botrule" colspan="3"><p class="First">*Creatinine clearance for patients not receiving hemodialysis <br>**0.75 g (0.67 g piperacillin/0.08 g tazobactam) should be administered following each hemodialysis session on hemodialysis days</p></td></tr>
</tbody>
</table>
<p>For patients on hemodialysis, the maximum dose is 2.25 g every twelve hours for all indications other than <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">nosocomial pneumonia</span> and 2.25 g every eight hours for <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">nosocomial pneumonia</span>.  Since hemodialysis removes 30% to 40% of the administered dose, an additional dose of 0.75 g piperacillin and tazobactam for injection (0.67 g piperacillin/0.08 g tazobactam) should be administered following each dialysis period on hemodialysis days.  No additional dosage of piperacillin and tazobactam for injection is necessary for CAPD patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_72092c0e-4d2b-42da-aec2-4d54e9e8e614"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Pediatric Patients</h2>
<p class="First">For children with <span class="product-label-link" type="condition" conceptid="440448" conceptname="Appendicitis">appendicitis</span> and/or <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span> 9 months of age or older, weighing up to 40 kg, and with normal renal function, the recommended piperacillin and tazobactam for injection dosage is 100 mg piperacillin/12.5 mg tazobactam per kilogram of body weight, every 8 hours.  For pediatric patients between 2 months and 9 months of age, the recommended piperacillin and tazobactam for injection dosage based on pharmacokinetic modeling, is 80 mg piperacillin/10 mg tazobactam per kilogram of body weight, every 8 hours [<span class="Italics">see Use in Specific Populations (<a href="#LINK_ec23e3d5-187d-45d1-b8e1-6be6cad6f7c1">8.4</a>) and Clinical Pharmacology (<a href="#LINK_cd6f60c3-464c-4e4e-8acf-e606d0816744">12.3</a>)</span>].  Pediatric patients weighing over 40 kg and with normal renal function should receive the adult dose.  It has not been determined how to adjust piperacillin and tazobactam for injection dosage in pediatric patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e7829199-e3d1-4ec5-9e3e-c3c166842cbb"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Reconstitution and Dilution of Powder Formulations</h2>
<p class="First"><span class="Bold">Pharmacy Bulk Package Bottles </span></p>
<p>Reconstituted stock solution must be transferred and further diluted for intravenous infusion.</p>
<p>The pharmacy bulk package bottle is for use in a hospital pharmacy admixture service only under a laminar flow hood.  After reconstitution, entry into the vial must be made with a sterile transfer set or other sterile dispensing device, and contents should be dispensed as aliquots into intravenous solution using aseptic technique.  Use entire contents of pharmacy bulk package bottle promptly.  Discard unused portion after 24 hours if stored at room temperature 20°C to 25°C (68°F to 77°F), or after 48 hours if stored at refrigerated temperature 2°C to 8°C (36°F to 46°F).</p>
<p>Reconstitute the pharmacy bulk package bottle with exactly 152 mL of a compatible reconstitution diluent, listed below, to a concentration of 200 mg/mL of piperacillin and 25 mg/mL of tazobactam.  Shake well until dissolved.  Parenteral drug products should be inspected visually for particulate matter and discoloration prior to and during administration whenever solution and container permit.</p>
<p><span class="Underline">Compatible Reconstitution Diluents for Pharmacy Bulk Bottles</span><br>0.9% Sodium chloride for injection<br>Sterile water for injection<span class="Sup">‡</span><br>Dextrose 5%<br>Bacteriostatic saline/parabens<br>Bacteriostatic water/parabens<br>Bacteriostatic saline/benzyl alcohol<br>Bacteriostatic water/benzyl alcohol </p>
<p>Reconstituted piperacillin and tazobactam for injection solution should be further diluted (recommended volume per dose of 50 mL to 150 mL) in a compatible intravenous solution listed below.  Administer by infusion over a period of at least 30 minutes.  During the infusion it is desirable to discontinue the primary infusion solution. </p>
<p><span class="Underline">Compatible Intravenous Solutions for Pharmacy Bulk Package Bottles and Single Dose Vials </span><br>0.9% Sodium chloride for injection<br>Sterile water for injection<span class="Sup">‡</span><br>Dextran 6% in saline<br>Dextrose 5%</p>
<p><span class="Bold"><span class="Underline">LACTATED RINGER’S SOLUTION IS NOT COMPATIBILE WITH PIPERACILLIN AND TAZOBACTAM FOR INJECTION</span>.</span></p>
<p><span class="Sup">‡ </span>Maximum recommended volume per dose of sterile water for injection is 50 mL.</p>
<p>Piperacillin and tazobactam for injection should not be mixed with other drugs in a syringe or infusion bottle since compatibility has not been established.</p>
<p>Piperacillin and tazobactam for injection is not chemically stable in solutions that contain only sodium <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> and solutions that significantly alter the pH.</p>
<p>Piperacillin and tazobactam for injection should not be added to blood products or albumin hydrolysates.</p>
<p>Parenteral drug products should be inspected visually for particulate matter or discoloration prior to administration, whenever solution and container permit.</p>
<p>Stability of Piperacillin and Tazobactam for Injection Powder Formulations Following Reconstitution</p>
<p>Piperacillin and tazobactam for injection reconstituted from pharmacy bulk package bottles is stable in glass and plastic containers (plastic syringes, I.V. bags and tubing) when used with compatible diluents.  The pharmacy bulk package bottle should <span class="Bold">NOT </span>be frozen after reconstitution.  Discard unused portions after storage for 24 hours at room temperature or after storage for 48 hours at refrigerated temperature 2°C to 8°C (36°F to 46°F).</p>
<p>Pharmacy bulk package bottles should be used immediately after reconstitution.  Discard any unused portion after 24 hours if stored at room temperature 20°C to 25°C (68°F to 77°F),  or after 48 hours if stored at refrigerated temperature 2°C to 8°C (36°F to 46°F).  Pharmacy bulk package bottles should not be frozen after reconstitution.</p>
<p>Stability studies in the I.V. bags have demonstrated chemical stability (potency, pH of reconstituted solution and clarity of solution) for up to 24 hours at room temperature and up to one week at refrigerated temperature.  Piperacillin and tazobactam for injection contains no preservatives.  Appropriate consideration of aseptic technique should be used.</p>
<p>Piperacillin and tazobactam for injection reconstituted from bulk package bottles can be used in ambulatory intravenous infusion pumps.  Stability of piperacillin and tazobactam for injection in an ambulatory intravenous infusion pump has been demonstrated for a period of 12 hours at room temperature.  Each dose was reconstituted and diluted to a volume of 37.5 mL or 25 mL.  One-day supplies of dosing solution were aseptically transferred into the medication reservoir (I.V. bags or cartridge).  The reservoir was fitted to a preprogrammed ambulatory intravenous infusion pump per the manufacturer's instructions.  Stability of piperacillin and tazobactam for injection is not affected when administered using an ambulatory intravenous infusion pump.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2cb5da21-3f04-43ca-ad17-850b38624dd1"></a><a name="section-2.6"></a><p></p>
<h2>2.6 Compatibility with Aminoglycosides</h2>
<p class="First">Due to the <span class="Italics">in vitro </span>inactivation of aminoglycosides by piperacillin, piperacillin and tazobactam for injection and aminoglycosides are recommended for separate administration.  Piperacillin and tazobactam for injection and aminoglycosides should be reconstituted, diluted, and administered separately when concomitant therapy with aminoglycosides is indicated [<span class="Italics">see Drug Interactions (<a href="#LINK_2f9dbd2c-9dc0-4480-891f-444e50c34ea7">7.1</a>)</span>].</p>
<p>In circumstances where co-administration via Y-site is necessary, piperacillin and tazobactam is compatible for simultaneous coadministration via Y-site infusion only with the following aminoglycosides under the following conditions:</p>
<table width="100%">
<col width="17%">
<col width="18%">
<col width="23%">
<col width="23%">
<col width="19%">
<tbody class="Headless">
<tr class="First"><td class="Toprule" align="center" colspan="5"><p class="First"><span class="Bold">Table 2: Compatibility with Aminoglycosides</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Aminoglycoside</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Piperacillin and Tazobactam</span><br><span class="Bold">Dose</span><br><span class="Bold">(grams)</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Piperacillin and Tazobactam Diluent Volume (mL)</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Aminoglycoside Concentration Range<span class="Sup">a</span></span><br><span class="Bold">(mg/mL)</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">Acceptable Diluents</span></p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Amikacin</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.25, 3.375, 4.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50, 100, 150</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.75 – 7.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.9% sodium chloride or 5% dextrose</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Gentamicin</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.25, 3.375, 4.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50, 100 150</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.7 – 3.32</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.9% sodium chloride or 5% dextrose</p></td>
</tr>
<tr class="Last"><td class="Botrule" colspan="5"><p class="First"><span class="Sup">a</span>The concentration ranges in Table 2 are based on administration of the aminoglycoside in divided doses (10-15 mg/kg/day in two daily doses for amikacin and 3-5 mg/kg/day in three daily doses for gentamicin).  Administration of amikacin or gentamicin in a single daily dose or in doses exceeding those stated above via Y-site with piperacillin and tazobactam has not been evaluated.  See package insert for each aminoglycoside for complete Dosage and Administration instructions.</p></td></tr>
</tbody>
</table>
<p>Only the concentration and diluents for amikacin or gentamicin with the dosages of piperacillin and tazobactam for injection listed above have been established as compatible for coadministration via Y-site infusion.  Simultaneous coadministration via Y-site infusion in any manner other than listed above may result in inactivation of the aminoglycoside by piperacillin and tazobactam.</p>
<p>Piperacillin and tazobactam for injection is not compatible with tobramycin for simultaneous coadministration via Y-site infusion.  Compatibility of piperacillin and tazobactam with other aminoglycosides has not been established.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="LINK_abff6fc2-20a6-4b2f-b135-e774b8c3eef2"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">Piperacillin and tazobactam for injection is supplied as a white to off-white powder in bottles of the following sizes: </p>
<p>Each Piperacillin and Tazobactam for Injection 40.5 g pharmacy bulk bottle contains piperacillin sodium equivalent to 36 grams of piperacillin and tazobactam sodium equivalent to 4.5 grams tazobactam.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_d6471d7a-111b-48df-af25-62107057cb64"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">Piperacillin and tazobactam for injection is contraindicated in patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to any of the penicillins, cephalosporins, or β-lactamase inhibitors.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="LINK_5cf93e6f-4906-43a7-b51d-5bb376cfc034"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9554029a-f177-4048-a5e1-ebd502477458"></a><a name="section-5.1"></a><p></p>
<h2>5.1 <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></h2>
<p class="First">Serious and occasionally fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (anaphylactic/anaphylactoid) reactions (including <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>) have been reported in patients receiving therapy with piperacillin and tazobactam for injection.  These reactions are more likely to occur in individuals with a history of penicillin, cephalosporin, or carbapenem <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> or a history of sensitivity to multiple allergens.  Before initiating therapy with piperacillin and tazobactam for injection, careful inquiry should be made concerning previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>.  If an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> occurs, piperacillin and tazobactam for injection should be discontinued and appropriate therapy instituted.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7dd610ac-dcf2-445d-9af7-63ca3343d0a2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></h2>
<p class="First">Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, such as <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, have been reported in patients receiving piperacillin and tazobactam for injection.  If patients develop a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> they should be monitored closely and piperacillin and tazobactam for injection discontinued if lesions progress. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ea08149e-db44-469e-8d62-9499dba29914"></a><a name="section-5.3"></a><p></p>
<h2>5.3 <span class="Italics">Clostridium difficile</span> Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></h2>
<p class="First"><span class="Italics">Clostridium difficile </span>associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including piperacillin and tazobactam for injection, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.  Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>. </p>
<p><span class="Italics">C. difficile </span>produces toxins A and B which contribute to the development of CDAD.  Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile </span>cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibacterial drug use.  Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. </p>
<p>If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against <span class="Italics">C. difficile </span>may need to be discontinued.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_876b1068-1aa3-4811-84a7-542813a2ec9c"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Hematologic Effects</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> manifestations have occurred in some patients receiving β-lactam drugs, including piperacillin.  These reactions have sometimes been associated with abnormalities of coagulation tests such as clotting time, platelet aggregation and <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, and are more likely to occur in patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>.  If <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> manifestations occur, piperacillin and tazobactam for injection should be discontinued and appropriate therapy instituted.</p>
<p>The <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> associated with piperacillin and tazobactam for injection administration appears to be reversible and most frequently associated with prolonged administration.</p>
<p>Periodic assessment of hematopoietic function should be performed, especially with prolonged therapy, ie, ≥ 21 days [<span class="Italics">see Adverse Reactions (<a href="#LINK_d36cb5fd-0847-4c97-ae7d-546c6c482a88">6.1</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_831f9c30-3c1a-4c1f-8792-8af3f25cbc9a"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Central Nervous System Effects</h2>
<p class="First">As with other penicillins, patients may experience neuromuscular <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitability</span> or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> if higher than recommended doses are given intravenously (particularly in the presence of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_74fdf3ee-a81f-4aa6-b195-3a0db6e88288"></a><a name="section-5.6"></a><p></p>
<h2>5.6 Electrolyte Effects</h2>
<p class="First">Piperacillin and tazobactam for injection contains a total of 2.35 mEq (54 mg) of Na<span class="Sup">+ </span>per gram of piperacillin in the combination product.  This should be considered when treating patients requiring restricted salt intake.  Periodic electrolyte determinations should be performed in patients with low potassium reserves, and the possibility of <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span> should be kept in mind with patients who have potentially low potassium reserves and who are receiving cytotoxic therapy or diuretics.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2b559894-2a82-4f5b-a72b-add58c8c7ef7"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Development of Drug-Resistant Bacteria</h2>
<p class="First">Prescribing piperacillin and tazobactam for injection in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> is unlikely to provide benefit to the patient and increases the risk of development of drug-resistant bacteria.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_8f40395e-3a54-48c7-8196-61408c7b1600"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d36cb5fd-0847-4c97-ae7d-546c6c482a88"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>During the initial clinical investigations, 2621 patients worldwide were treated with piperacillin and tazobactam for injection in phase 3 trials.  In the key North American monotherapy clinical trials (n=830 patients), 90% of the adverse events reported were mild to moderate in severity and transient in nature.  However, in 3.2% of the patients treated worldwide, piperacillin and tazobactam for injection was discontinued because of adverse events primarily involving the skin (1.3%), including <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>; the gastrointestinal system (0.9%), including <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> (0.5%).</p>
<table width="100%">
<col width="77%">
<tbody class="Headless">
<tr class="First"><td class="Toprule" align="center"><p class="First"><span class="Bold">Table 3:  Adverse Reactions from Piperacillin and Tazobactam for Injection </span><br><span class="Bold">Monotherapy Clinical Trials</span></p></td></tr>
<tr><td class="Botrule"><p class="First"><span class="Bold">System Organ Class</span><br><span class="Bold">    </span>Adverse Reaction</p></td></tr>
<tr><td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span><br><span class="Bold">    </span><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> (11.3%)<br>    <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> (7.7%)<br>    <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> (6.9%)<br>    <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> (3.3%)<br>    <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span> (3.3%)<br>    <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> (1.3%)<br>    <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">Pseudomembranous colitis</span> (≤1%)</p></td></tr>
<tr><td><p class="First"><span class="Bold">General disorders and administration site conditions</span><br><span class="Bold">    </span><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> (2.4%)<br>    <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reaction</span> (≤1%)<br>    <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Rigors</span> (≤1%)</p></td></tr>
<tr><td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune system disorders</span></span><br><span class="Bold">    </span><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> (≤1%)</p></td></tr>
<tr><td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span><br><span class="Bold">    </span><span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candidiasis</span> (1.6%)</p></td></tr>
<tr><td><p class="First"><span class="Bold">Metabolism and nutrition disorders</span><br><span class="Bold">    </span><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> (≤1%)</p></td></tr>
<tr><td><p class="First"><span class="Bold">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span></span><br><span class="Bold">    </span><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>(≤1%)<br>    <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span> (≤1%)</p></td></tr>
<tr><td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span><br><span class="Bold">    </span><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> (7.7%)<br>    <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> (6.6%)</p></td></tr>
<tr><td><p class="First"><span class="Bold">Skin and subcutaneous tissue disorders</span><br><span class="Bold">    </span><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> (4.2%, including maculopapular, bullous, and urticarial)<br>    <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> (3.1%)</p></td></tr>
<tr class="Last"><td class="Botrule"><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></span><br><span class="Bold">    </span><span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">Phlebitis</span> (1.3%)<br>    <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">Thrombophlebitis</span> (≤1%)<br>    <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> (≤1%)<br>    <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">Purpura</span> (≤1%)<br>    <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span> (≤1%)<br>    <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span> (≤1%)</p></td></tr>
</tbody>
</table>
<p><span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Nosocomial Pneumonia</span> Trials</p>
<p>Two trials of nosocomial <span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">lower respiratory tract infections</span> were conducted.  In one study, 222 patients were treated with piperacillin and tazobactam for injection in a dosing regimen of 4.5 g every 6 hours in combination with an aminoglycoside and 215 patients were treated with imipenem/cilastatin (500 mg/500 mg q6h) in combination with an aminoglycoside.  In this trial, treatment-emergent adverse events were reported by 402 patients, 204 (91.9%) in the piperacillin/tazobactam group and 198 (92.1%) in the imipenem/cilastatin group.  Twenty-five (11.0%) patients in the piperacillin/tazobactam group and 14 (6.5%) in the imipenem/cilastatin group (p &gt; 0.05) discontinued treatment due to an adverse event. </p>
<p>The second trial used a dosing regimen of 3.375 g given every 4 hours with an aminoglycoside.</p>
<table width="100%">
<col width="87%">
<tbody class="Headless">
<tr class="First"><td class="Toprule" align="center"><p class="First"><span class="Bold">Table 4:  Adverse Reactions from Piperacillin and Tazobactam for Injection</span><br><span class="Bold">Plus Aminoglycoside Clinical Trials<span class="Sup">a</span></span></p></td></tr>
<tr><td class="Botrule"><p class="First"><span class="Bold">System Organ Class</span><br><span class="Bold">    </span>Adverse Reaction</p></td></tr>
<tr><td class="Botrule"><p class="First"><span class="Bold">Blood and lymphatic system disorders</span><br><span class="Bold">    </span><span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">Thrombocythemia</span> (1.4%)<br>    <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> (≤1%)<br>    <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span> (≤1%)<br>    <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">Eosinophilia</span> (≤1%)</p></td></tr>
<tr><td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span></span><br><span class="Bold">    </span><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> (20%)<br>    <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span> (8.4%)<br>    <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> (5.8%)<br>    <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span> (2.7%)<br>    <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span> (1.9%)<br>    <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span> (1.8%)<br>    <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span> (≤1%)</p></td></tr>
<tr><td><p class="First"><span class="Bold">General disorders and administration site conditions</span><br><span class="Bold">    </span><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span> (3.2%)<br>    <span class="product-label-link" type="condition" conceptid="4316202" conceptname="Injection site reaction">Injection site reaction</span> (≤1%)</p></td></tr>
<tr><td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span></span><br><span class="Bold">    </span><span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">Oral candidiasis</span> (3.9%)<br>    <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Candidiasis</span> (1.8%)</p></td></tr>
<tr><td><p class="First"><span class="Bold">Investigations</span><br><span class="Bold">    </span>BUN increased (1.8%)<br>    Blood creatinine increased (1.8%)<br>    <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">Liver function test abnormal</span> (1.4%)<br>    Alkaline phosphatase increased (≤1%)<br>    <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">Aspartate aminotransferase</span> increased (≤1%)<br>    <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">Alanine aminotransferase</span> increased (≤1%)</p></td></tr>
<tr><td><p class="First"><span class="Bold">Metabolism and nutrition disorders</span><br><span class="Bold">    </span><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span> (≤1%)<br>    <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> (≤1%)</p></td></tr>
<tr><td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span></span><br><span class="Bold">    </span><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> (4.5%)<br>    <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> (4.5%)</p></td></tr>
<tr><td><p class="First"><span class="Bold">Renal and urinary disorders</span><br><span class="Bold">    </span><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal failure</span> (≤1%)</p></td></tr>
<tr><td><p class="First"><span class="Bold">Skin and subcutaneous tissue disorders</span><br><span class="Bold">    </span><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> (3.9%)<br>    <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span> (3.2%)</p></td></tr>
<tr><td><p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></span><br><span class="Bold">    </span><span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">Thrombophlebitis</span> (1.3%)<br>    <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> (1.3%)</p></td></tr>
<tr class="Last"><td class="Botrule"><p class="First"><span class="Sup">a </span>For adverse drug reactions that appeared in both studies the higher frequency is presented.</p></td></tr>
</tbody>
</table>
<p>Pediatrics</p>
<p>Studies of piperacillin and tazobactam for injection in pediatric patients suggest a similar safety profile to that seen in adults.  In a prospective, randomized, comparative, open-label clinical trial of pediatric patients with severe intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">abdominal infections</span> (including <span class="product-label-link" type="condition" conceptid="440448" conceptname="Appendicitis">appendicitis</span> and/or <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span>), 273 patients were treated with piperacillin and tazobactam for injection (112.5 mg/kg every 8 hours) and 269 patients were treated with cefotaxime (50 mg/kg) plus metronidazole (7.5 mg/kg) every 8 hours.  In this trial, treatment-emergent adverse events were reported by 146 patients, 73 (26.7%) in the piperacillin and tazobactam for injection group and 73 (27.1%) in the cefotaxime/metronidazole group.  Six patients (2.2%) in the piperacillin and tazobactam for injection group and 5 patients (1.9%) in the cefotaxime/metronidazole group discontinued due to an adverse event. </p>
<p>Adverse Laboratory Events (Seen During Clinical Trials) </p>
<p>Of the trials reported, including that of nosocomial <span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">lower respiratory tract infections</span> in which a higher dose of piperacillin and tazobactam for injection was used in combination with an aminoglycoside, changes in laboratory parameters include: </p>
<p><span class="Italics">Hematologic</span>—decreases in hemoglobin and hematocrit, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, increases in platelet count, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>.  These patients were withdrawn from therapy; some had accompanying systemic symptoms (e.g., <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">rigors</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>). </p>
<p><span class="Italics">Coagulation</span>—positive direct Coombs' test, prolonged <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, prolonged partial thromboplastin time</p>
<p><span class="Italics">Hepatic</span>—transient elevations of AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>), ALT (SGPT), alkaline phosphatase, bilirubin</p>
<p><span class="Italics">Renal</span>—increases in serum creatinine, blood urea nitrogen</p>
<p>Additional laboratory events include abnormalities in electrolytes (i.e., increases and decreases in sodium, potassium, and calcium), <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, decreases in total protein or albumin, blood glucose decreased, gamma-glutamyltransferase increased, <span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">hypokalemia</span>, and <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> prolonged.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f5ceefcc-2eee-4421-87ff-8075b13374b2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Post-Marketing Experience</h2>
<p class="First">In addition to the adverse drug reactions identified in clinical trials in Table 3 and Table 4, the following adverse reactions have been identified during postapproval use of piperacillin and tazobactam for injection. </p>
<p>Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish causal relationship to drug exposure. </p>
<p><span class="Italics">Gastrointestinal</span>—<span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span></p>
<p><span class="Italics">Hematologic</span>—<span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span></p>
<p><span class="Italics">Immune</span>—<span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, anaphylactic/<span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> (including <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>)</p>
<p><span class="Italics">Renal</span>—interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span></p>
<p><span class="Italics">Skin and Appendages</span>—<span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2bd923ff-fe58-46d2-8181-48b2b1b8493c"></a><a name="section-6.3"></a><p></p>
<h2>6.3 Additional Experience with piperacillin</h2>
<p class="First">The following adverse reaction has also been reported for piperacillin for injection: </p>
<p><span class="Italics">Skeletal</span>—prolonged <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">muscle relaxation</span> [<span class="Italics">see Drug Interactions (<a href="#LINK_f32a7553-066c-4cfc-a468-ec9029aa9f21">7.4</a>)]. </span></p>
<p>Post-marketing experience with piperacillin and tazobactam for injection in pediatric patients suggests a similar safety profile to that seen in adults.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_19a570b8-cdb7-42e4-8513-96942f183292"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2f9dbd2c-9dc0-4480-891f-444e50c34ea7"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Aminoglycosides</h2>
<p class="First">Piperacillin may inactivate aminoglycosides by converting them to microbiologically inert amides.</p>
<p><span class="Italics">In vivo </span>inactivation<span class="Italics">: </span>When aminoglycosides are administered in conjunction with piperacillin to patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> requiring hemodialysis, the concentrations of the aminoglycosides (especially tobramycin) may be significantly reduced and should be monitored. </p>
<p>Sequential administration of piperacillin and tazobactam for injection and tobramycin to patients with either normal renal function or mild to moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> has been shown to modestly decrease serum concentrations of tobramycin but no dosage adjustment is considered necessary.</p>
<p><span class="Italics">In vitro</span> inactivation:</p>
<p>Due to the <span class="Italics">in vitro </span>inactivation of aminoglycosides by piperacillin, piperacillin and tazobactam for injection and aminoglycosides are recommended for separate administration.  Piperacillin and tazobactam for injection and aminoglycosides should be reconstituted, diluted, and administered separately when concomitant therapy with aminoglycosides is indicated.  Piperacillin and tazobactam for injection is compatible with amikacin and gentamicin for simultaneous Y-site infusion in certain diluents and at specific concentrations.  Piperacillin and tazobactam for injection is not compatible with tobramycin for simultaneous Y-site infusion [<span class="Italics">see Dosage and Administration (<a href="#LINK_2cb5da21-3f04-43ca-ad17-850b38624dd1">2.6</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_8e4d6a5e-7693-4f2d-bc83-0f0344282aea"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Probenecid</h2>
<p class="First">Probenecid administered concomitantly with piperacillin and tazobactam prolongs the half-life of piperacillin by 21% and that of tazobactam by 71% because probenecid inhibits tubular renal secretion of both piperacillin and tazobactam.  Probenecid should not be co-administered with piperacillin and tazobactam for injection unless the benefit outweighs the risk.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a47a8645-d911-4034-987c-53ca313b5577"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Anticoagulants</h2>
<p class="First">Coagulation parameters should be tested more frequently and monitored regularly during simultaneous administration of high doses of heparin, oral anticoagulants, or other drugs that may affect the blood coagulation system or the thrombocyte function. [<span class="Italics">see Warnings and Precautions (<a href="#LINK_876b1068-1aa3-4811-84a7-542813a2ec9c">5.4</a>)</span>]</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f32a7553-066c-4cfc-a468-ec9029aa9f21"></a><a name="section-7.4"></a><p></p>
<h2>7.4 Vecuronium</h2>
<p class="First">Piperacillin when used concomitantly with vecuronium has been implicated in the prolongation of the <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> of vecuronium.  Piperacillin and tazobactam for injection could produce the same phenomenon if given along with vecuronium.  Due to their similar mechanism of action, it is expected that the <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> produced by any of the non-depolarizing muscle relaxants could be prolonged in the presence of piperacillin.  Monitor for adverse reactions related to <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> (See package insert for vecuronium bromide).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_8d24b592-e1a8-4461-940a-96baf9f9bb21"></a><a name="section-7.5"></a><p></p>
<h2>7.5 Methotrexate</h2>
<p class="First">Limited data suggests that co-administration of methotrexate and piperacillin may reduce the clearance of methotrexate due to competition for renal secretion.  The impact of tazobactam on the elimination of methotrexate has not been evaluated.  If concurrent therapy is necessary, serum concentrations of methotrexate as well as the signs and symptoms of methotrexate toxicity should be frequently monitored.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4f6b4eae-2bd6-48bb-8092-662c9fab9270"></a><a name="section-7.6"></a><p></p>
<h2>7.6 Effects on Laboratory Tests</h2>
<p class="First">There have been reports of positive test results using the Bio-Rad Laboratories Platelia <span class="Italics">Aspergillus </span>EIA test in patients receiving piperacillin/tazobactam injection who were subsequently found to be free of <span class="Italics">Aspergillus</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.  Cross-reactions with non-<span class="Italics">Aspergillus</span> polysaccharides and polyfuranoses with the Bio-Rad Laboratories Platelia <span class="Italics">Aspergillus</span> EIA test have been reported.  Therefore, positive test results in patients receiving piperacillin/tazobactam should be interpreted cautiously and confirmed by other diagnostic methods.</p>
<p>As with other penicillins, the administration of piperacillin and tazobactam for injection may result in a false-positive reaction for glucose in the urine using a copper-reduction method (CLINITEST<span class="Sup">®</span>).  It is recommended that glucose tests based on enzymatic glucose oxidase reactions be used.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="LINK_406c9b2c-c20f-4045-a675-036f9ea1d049"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_e603fb28-110b-4d21-b0f6-47ce4c495b8c"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<p class="First">Teratogenic effects—Pregnancy Category B </p>
<p><span class="Italics">Piperacillin/tazobactam </span></p>
<p>Teratology studies have been performed in mice and rats and have revealed no evidence of harm to the fetus when piperacillin/tazobactam is administered intravenously up to a dose of 3000/750 mg/kg piperacillin/tazobactam which is 1 to 2 times and 2 to 3 times the human dose of piperacillin and tazobactam, respectively, based on body-surface area (mg/m<span class="Sup">2</span>). </p>
<p>Piperacillin and tazobactam cross the placenta in humans. </p>
<p>There are, however, no adequate and well-controlled studies with the piperacillin/tazobactam combination or with piperacillin or tazobactam alone in pregnant women.  Because animal reproduction studies are not always predictive of the human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_512bfb9a-b72e-4044-be0c-0c833d4a25d4"></a><a name="section-8.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Piperacillin is excreted in low concentrations in human milk; tazobactam concentrations in human milk have not been studied.  Caution should be exercised when piperacillin and tazobactam for injection is administered to a nursing woman. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_ec23e3d5-187d-45d1-b8e1-6be6cad6f7c1"></a><a name="section-8.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Use of piperacillin and tazobactam for injection in pediatric patients 2 months of age or older with <span class="product-label-link" type="condition" conceptid="440448" conceptname="Appendicitis">appendicitis</span> and/or <span class="product-label-link" type="condition" conceptid="196152" conceptname="Peritonitis">peritonitis</span> is supported by evidence from well-controlled studies and pharmacokinetic studies in adults and in pediatric patients.  This includes a prospective, randomized, comparative, open-label clinical trial with 542 pediatric patients 2-12 years of age with complicated intra-<span class="product-label-link" type="condition" conceptid="4028062" conceptname="Infectious disease of abdomen">abdominal infections</span>, in which 273 pediatric patients received piperacillin/tazobactam.  Safety and efficacy in pediatric patients less than 2 months of age have not been established [<span class="Italics">see Clinical Pharmacology (<a href="#LINK_107ed3b8-9a04-4cef-adbe-9ee8a66c84de">12</a>) and Dosage and Administration (<a href="#LINK_1803439c-d626-4421-ae9c-cd667a0cf47e">2</a>)</span>].</p>
<p>It has not been determined how to adjust piperacillin and tazobactam for injection dosage in pediatric patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_f56ccb9c-1451-4d16-8e84-5dc51d6e87dd"></a><a name="section-8.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Patients over 65 years are not at an increased risk of developing adverse effects solely because of age.  However, dosage should be adjusted in the presence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> [<span class="Italics">see Dosage and Administration (<a href="#LINK_1803439c-d626-4421-ae9c-cd667a0cf47e">2</a>)</span>].</p>
<p>In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
<p>Piperacillin and tazobactam for injection contains 54 mg (2.35 mEq) of sodium per gram of piperacillin in the combination product.  At the usual recommended doses, patients would receive between 648 and 864 mg/day (28.2 and 37.6 mEq) of sodium.  The geriatric population may respond with a blunted natriuresis to salt loading.  This may be clinically important with regard to such diseases as <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>.</p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.  Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a03893ac-ef43-4867-aacd-20493e352c54"></a><a name="section-8.5"></a><p></p>
<h2>8.6 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">In patients with creatinine clearance ≤ 40 mL/min and dialysis patients (hemodialysis and CAPD), the intravenous dose of piperacillin and tazobactam for injection should be reduced to the degree of renal function impairment [<span class="Italics">see Dosage and Administration (<a href="#LINK_1803439c-d626-4421-ae9c-cd667a0cf47e">2</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_1e73c930-c6c3-4e81-93e6-df4419f8dafd"></a><a name="section-8.6"></a><p></p>
<h2>8.7 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">Dosage adjustment of piperacillin and tazobactam for injection is not warranted in patients with <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span> [See <span class="Italics">Clinical Pharmacology (<a href="#LINK_cd6f60c3-464c-4e4e-8acf-e606d0816744">12.3</a></span>)]. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_0293aba3-f810-4d57-a2ae-ca4ffc7552ff"></a><a name="section-8.7"></a><p></p>
<h2>8.8 Patients with <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">Cystic Fibrosis</span></h2>
<p class="First">As with other semisynthetic penicillins, piperacillin therapy has been associated with an increased incidence of <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> in <span class="product-label-link" type="condition" conceptid="441267" conceptname="Cystic fibrosis">cystic fibrosis</span> patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_a59f7616-384a-40a5-adc4-bdeab862dab8"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First">There have been postmarketing reports of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> with piperacillin/tazobactam.  The majority of those events experienced, including <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, have also been reported with the usual recommended dosages. Patients may experience neuromuscular <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitability</span> or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> if higher than recommended doses are given intravenously (particularly in the presence of <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>) [<span class="Italics">see Warnings and Precautions (<a href="#LINK_831f9c30-3c1a-4c1f-8792-8af3f25cbc9a">5.5</a>)</span>]. </p>
<p>Treatment should be supportive and symptomatic according the patient's clinical presentation. Excessive serum concentrations of either piperacillin or tazobactam may be reduced by hemodialysis.  Following a single 3.375 g dose of piperacillin/tazobactam, the percentage of the piperacillin and tazobactam dose removed by hemodialysis was approximately 31% and 39%, respectively [<span class="Italics">see Clinical Pharmacology (<a href="#LINK_107ed3b8-9a04-4cef-adbe-9ee8a66c84de">12</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_66ac1021-ae82-4e04-89f2-f746cd366602"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Piperacillin and tazobactam for injection is an injectable antibacterial combination product consisting of the semisynthetic antibacterial piperacillin sodium and the β-lactamase inhibitor tazobactam sodium for intravenous administration.</p>
<p>Piperacillin sodium is derived from D(-)-α-aminobenzyl-penicillin.  The chemical name of piperacillin sodium is sodium (2<span class="Italics">S</span>,5<span class="Italics">R</span>,6<span class="Italics">R</span>)-6-[(<span class="Italics">R</span>)-2-(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)-2-phenylacetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate.  The chemical formula is C<span class="Sub">23</span>H<span class="Sub">26</span>N<span class="Sub">5</span>NaO<span class="Sub">7</span>S and the molecular weight is 539.5.  The chemical structure of piperacillin sodium is:</p>
<div class="Figure">
<a name="id1146"></a><img alt="chemical structure of piperacillin sodium" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e53ebafc-3afa-4a1e-9313-fecd1c1c5d7c&amp;name=piperacillin-and-tazobactam-for-injection-anda-090-1.jpg">
</div>
<p>Tazobactam sodium, a derivative of the penicillin nucleus, is a penicillanic acid sulfone.  Its chemical name is sodium (2<span class="Italics">S,</span>3<span class="Italics">S,</span>5<span class="Italics">R</span>)-3-methyl-7-oxo-3-(1<span class="Italics">H</span>-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate-4,4-dioxide.  The chemical formula is C<span class="Sub">10</span>H<span class="Sub">11</span>N<span class="Sub">4</span>NaO<span class="Sub">5</span>S and the molecular weight is 322.3.  The chemical structure of tazobactam sodium is:</p>
<div class="Figure">
<a name="id1156"></a><img alt="chemical structure of tazobactam sodium" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e53ebafc-3afa-4a1e-9313-fecd1c1c5d7c&amp;name=piperacillin-and-tazobactam-for-injection-anda-090-2.jpg">
</div>
<p>Piperacillin and tazobactam for injection, piperacillin/tazobactam parenteral combination, is a white to off-white sterile, cryodesiccated powder consisting of piperacillin and tazobactam as their sodium salts packaged in glass bottles.  The product does not contain excipients or preservatives.</p>
<p>The pharmacy bulk package bottle is a container of sterile preparation which contains many single doses for parenteral use.  The contents are intended for use in a pharmacy admixture program and are restricted to the preparation of admixtures for intravenous infusion.</p>
<p>Each piperacillin and tazobactam for injection 40.5 g pharmacy bulk package bottle contains piperacillin sodium equivalent to 36 grams of piperacillin and tazobactam sodium equivalent to 4.5 g of tazobactam sufficient for delivery of multiple doses.</p>
<p>Piperacillin and tazobactam for injection is a monosodium salt of piperacillin and a monosodium salt of tazobactam containing a total of 2.35 mEq (54 mg) of sodium (Na<span class="Sup">+</span>) per gram of piperacillin in the combination product.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_107ed3b8-9a04-4cef-adbe-9ee8a66c84de"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="LINK_9f24b1dc-286a-419c-86f6-f7499420ad8b"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Piperacillin and tazobactam for injection is an antibacterial drug [<span class="Italics">see Microbiology (<a href="#LINK_78f2f810-79ac-4446-8454-c54a4af05271">12.4</a>)</span>]. </p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="LINK_9dd7e96e-1376-44a5-80dd-11eff3a7f37c"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">The pharmacodynamic parameter for piperacillin/tazobactam that is most predictive of clinical and microbiological efficacy is time above MIC.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_cd6f60c3-464c-4e4e-8acf-e606d0816744"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The mean and coefficients of variation (CV%) for the pharmacokinetic parameters of piperacillin and tazobactam after multiple intravenous doses are summarized in Table 5.</p>
<table width="100%">
<col width="26%">
<col width="10%">
<col width="12%">
<col width="10%">
<col width="7%">
<col width="7%">
<col width="10%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Toprule" align="center" colspan="7"><p class="First"><span class="Bold">Table 5:  Mean (CV%) Piperacillin and Tazobactam PK Parameters Piperacillin</span></p></td></tr>
<tr><td class="Botrule" align="center" colspan="7"><p class="First"><span class="Bold">Piperacillin</span></p></td></tr>
<tr>
<td class="Botrule"><p class="First">Piperacillin/Tazobactam<br>Dose<span class="Sup">a</span></p></td>
<td class="Botrule" align="center" valign="bottom"><p class="First">C<span class="Sub">max</span><br>mcg/mL</p></td>
<td class="Botrule" align="center" valign="bottom"><p class="First">AUC<span class="Sub">b</span><br>mcg•h/mL</p></td>
<td class="Botrule" align="center" valign="bottom"><p class="First">CL<br>mL/min</p></td>
<td class="Botrule" align="center" valign="bottom"><p class="First">V<br>L</p></td>
<td class="Botrule" align="center" valign="bottom"><p class="First">T<span class="Sub">1/2</span><br>h</p></td>
<td class="Botrule" align="center" valign="bottom"><p class="First">CL<span class="Sub">R</span><br>mL/min</p></td>
</tr>
<tr>
<td><p class="First">2.25 g</p></td>
<td align="center"><p class="First">134</p></td>
<td align="center"><p class="First">131 (14)</p></td>
<td align="center"><p class="First">257</p></td>
<td align="center"><p class="First">17.4</p></td>
<td align="center"><p class="First">0.79</p></td>
<td align="center"><p class="First">-</p></td>
</tr>
<tr>
<td><p class="First">3.375 g</p></td>
<td align="center"><p class="First">242</p></td>
<td align="center"><p class="First">242 (10)</p></td>
<td align="center"><p class="First">207</p></td>
<td align="center"><p class="First">15.1</p></td>
<td align="center"><p class="First">0.84</p></td>
<td align="center"><p class="First">140</p></td>
</tr>
<tr>
<td><p class="First">4.5 g</p></td>
<td align="center"><p class="First">298</p></td>
<td align="center"><p class="First">322 (16)</p></td>
<td align="center"><p class="First">210</p></td>
<td align="center"><p class="First">15.4</p></td>
<td align="center"><p class="First">0.84</p></td>
<td align="center"><p class="First">-</p></td>
</tr>
<tr><td class="Botrule" align="center" colspan="7"><p class="First"><span class="Bold">Tazobactam</span></p></td></tr>
<tr>
<td class="Botrule"><p class="First">Piperacillin/Tazobactam<br>Dose<span class="Sup">a</span></p></td>
<td class="Botrule" align="center" valign="bottom"><p class="First">C<span class="Sub">max</span><br>mcg/mL</p></td>
<td class="Botrule" align="center" valign="bottom"><p class="First">AUC<span class="Sub">b</span><br>mcg•h/mL</p></td>
<td class="Botrule" align="center" valign="bottom"><p class="First">CL<br>mL/min</p></td>
<td class="Botrule" align="center" valign="bottom"><p class="First">V<br>L</p></td>
<td class="Botrule" align="center" valign="bottom"><p class="First">T<span class="Sub">1/2</span><br>h</p></td>
<td class="Botrule" align="center" valign="bottom"><p class="First">CL<span class="Sub">R</span><br>mL/min</p></td>
</tr>
<tr>
<td><p class="First">2.25 g</p></td>
<td align="center"><p class="First">15</p></td>
<td align="center"><p class="First">16.0 (21)</p></td>
<td align="center"><p class="First">258</p></td>
<td align="center"><p class="First">17.0</p></td>
<td align="center"><p class="First">0.77</p></td>
<td align="center"><p class="First">-</p></td>
</tr>
<tr>
<td><p class="First">3.375 g</p></td>
<td align="center"><p class="First">24</p></td>
<td align="center"><p class="First">25.0 (8)</p></td>
<td align="center"><p class="First">251</p></td>
<td align="center"><p class="First">14.8</p></td>
<td align="center"><p class="First">0.68</p></td>
<td align="center"><p class="First">166</p></td>
</tr>
<tr>
<td><p class="First">4.5 g</p></td>
<td align="center"><p class="First">34</p></td>
<td align="center"><p class="First">39.8 (15)</p></td>
<td align="center"><p class="First">206</p></td>
<td align="center"><p class="First">14.7</p></td>
<td align="center"><p class="First">0.82</p></td>
<td align="center" valign="bottom"><p class="First">-</p></td>
</tr>
<tr class="Last"><td class="Botrule" colspan="7"><p class="First"><span class="Sup">a</span>Piperacillin and tazobactam were given in combination, infused over 30 minutes.<br><span class="Sup">b</span>Numbers in parentheses are coefficients of variation (CV%).</p></td></tr>
</tbody>
</table>
<p>Peak plasma concentrations of piperacillin and tazobactam are attained immediately after completion of an intravenous infusion of piperacillin and tazobactam for injection.  Piperacillin plasma concentrations, following a 30-minute infusion of piperacillin and tazobactam for injection, were similar to those attained when equivalent doses of piperacillin were administered alone. Steady-state plasma concentrations of piperacillin and tazobactam were similar to those attained after the first dose due to the short half-lives of piperacillin and tazobactam.</p>
<p>Distribution</p>
<p>Both piperacillin and tazobactam are approximately 30% bound to plasma proteins.  The protein binding of either piperacillin or tazobactam is unaffected by the presence of the other compound. Protein binding of the tazobactam metabolite is negligible.</p>
<p>Piperacillin and tazobactam are widely distributed into tissues and body fluids including intestinal mucosa, gallbladder, lung, female reproductive tissues (uterus, ovary, and fallopian tube), interstitial fluid, and bile.  Mean tissue concentrations are generally 50% to 100% of those in plasma.  Distribution of piperacillin and tazobactam into cerebrospinal fluid is low in subjects with non-inflamed meninges, as with other penicillins (see Table 6).</p>
<table width="100%">
<col width="15%">
<col width="4%">
<col width="12%">
<col width="19%">
<col width="16%">
<col width="17%">
<col width="17%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="7"><p class="First"><span class="Bold">Table 6:  Piperacillin/Tazobactam Concentrations in Selected Tissues and Fluids after</span><br><span class="Bold">Single 4 g/0.5 g 30-min IV Infusion of Piperacillin and Tazobactam for Injection</span></p></td></tr>
<tr>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">Tissue or Fluid</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">N<span class="Sup">a</span></p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">Sampling period<span class="Sup">b</span><br>(h)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Mean PIP Concentration Range<br>(mg/L)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">Tissue:Plasma Range</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Tazo Concentration Range<br>(mg/L)</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">Tazo Tissue:Plasma Range</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Skin</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">35</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.5 – 4.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">34.8 – 94.2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.60 – 1.1</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4.0 – 7.7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.49 – 0.93</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Fatty Tissue</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">37</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.5 – 4.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4.0 – 10.1</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.097 – 0.115</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.7 – 1.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.10 – 0.13</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Muscle </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">36</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.5 – 4.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9.4 – 23.3</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.29 – 0.18</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.4 – 2.7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.18 – 0.30</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Proximal Intestinal Mucosa</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.5 – 2.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">31.4</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.55</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10.3</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.15</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Distal Intestinal Mucosa</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.5 – 2.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">31.2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.59</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">14.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2.1</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule"><p class="First">Appendix</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">22</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.5 – 2.5</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">26.5 – 64.1</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.43 – 0.53</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9.1 – 18.6</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.80 – 1.35</p></td>
</tr>
<tr class="Last"><td class="Botrule Lrule Rrule" colspan="7"><p class="First"><span class="Sup">a</span> Each subject provided a single sample.<br><span class="Sup">b</span> Time from the start of the infusion </p></td></tr>
</tbody>
</table>
<p>Metabolism</p>
<p>Piperacillin is metabolized to a minor microbiologically active desethyl metabolite.  Tazobactam is metabolized to a single metabolite that lacks pharmacological and antibacterial activities.</p>
<p>Excretion</p>
<p>Following single or multiple piperacillin and tazobactam for injection doses to healthy subjects, the plasma half-life of piperacillin and of tazobactam ranged from 0.7 to 1.2 hours and was unaffected by dose or duration of infusion.</p>
<p>Both piperacillin and tazobactam are eliminated via the kidney by glomerular filtration and tubular secretion.  Piperacillin is excreted rapidly as unchanged drug with 68% of the administered dose excreted in the urine.  Tazobactam and its metabolite are eliminated primarily by renal excretion with 80% of the administered dose excreted as unchanged drug and the remainder as the single metabolite.  Piperacillin, tazobactam and desethyl piperacillin are also secreted into the bile.</p>
<p>Specific Populations</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span></span></p>
<p>After the administration of single doses of piperacillin/tazobactam to subjects with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the half-life of piperacillin and of tazobactam increases with decreasing creatinine clearance.  At creatinine clearance below 20 mL/min, the increase in half-life is twofold for piperacillin and fourfold for tazobactam compared to subjects with normal renal function.  Dosage adjustments for piperacillin and tazobactam for injection are recommended when creatinine clearance is below 40 mL/min in patients receiving the usual recommended daily dose of piperacillin and tazobactam for injection.  <span class="Italics">See Dosage and Administration (<a href="#LINK_1803439c-d626-4421-ae9c-cd667a0cf47e">2</a>) </span>for specific recommendations for the treatment of patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p>Hemodialysis removes 30% to 40% of a piperacillin/tazobactam dose with an additional 5% of the tazobactam dose removed as the tazobactam metabolite.  Peritoneal dialysis removes approximately 6% and 21% of the piperacillin and tazobactam doses, respectively, with up to 16% of the tazobactam dose removed as the tazobactam metabolite.  For dosage recommendations for patients undergoing hemodialysis [<span class="Italics">see Dosage and Administration (<a href="#LINK_1803439c-d626-4421-ae9c-cd667a0cf47e">2</a>)</span>.]</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> </span></p>
<p>The half-life of piperacillin and of tazobactam increases by approximately 25% and 18%, respectively, in patients with <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span> compared to healthy subjects.  However, this difference does not warrant dosage adjustment of piperacillin and tazobactam for injection due to <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span>.</p>
<p><span class="Italics">Pediatrics</span></p>
<p>Piperacillin and tazobactam pharmacokinetics were studied in pediatric patients 2 months of age and older.  The clearance of both compounds is slower in the younger patients compared to older children and adults.</p>
<p>In a population PK analysis, estimated clearance for 9 month-old to 12 year-old patients was comparable to adults, with a population mean (SE) value of 5.64 (0.34) mL/min/kg.  The piperacillin clearance estimate is 80% of this value for pediatric patients 2-9 months old.  In patients younger than 2 months of age, clearance of piperacillin is slower compared to older children; however, it is not adequately characterized for dosing recommendations.  The population mean (SE) for piperacillin distribution volume is 0.243 (0.011) L/kg and is independent of age.</p>
<p><span class="Italics">Geriatrics</span></p>
<p>The impact of age on the pharmacokinetics of piperacillin and tazobactam was evaluated in healthy male subjects, aged 18-35 years (n=6) and aged 65 to 80 years (n=12).  Mean half-life for piperacilln and tazobactam was 32% and 55% higher, respectively, in the elderly compared to the younger subjects.  This difference may be due to age-related changes in creatinine clearance.</p>
<p><span class="Italics">Race</span></p>
<p>The effect of race on piperacillin and tazobactam was evaluated in healthy male volunteers.  No difference in piperacillin or tazobactam pharmacokinetics was observed between Asian (n=9) and Caucasian (n=9) healthy volunteers who received single 4/0.5 g doses.</p>
<p>Drug Interactions</p>
<p>The potential for pharmacokinetic drug interactions between piperacillin and tazobactam for injection and aminoglycosides, probenecid, vancomycin, heparin, vecuronium, and methotrexate has been evaluated [<span class="Italics">see Drug Interactions (<a href="#LINK_19a570b8-cdb7-42e4-8513-96942f183292">7</a>)</span>].</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_78f2f810-79ac-4446-8454-c54a4af05271"></a><a name="section-11.4"></a><p></p>
<h2>12.4 Microbiology</h2>
<p class="First">Mechanism of Action</p>
<p>Piperacillin sodium exerts bactericidal activity by inhibiting septum formation and cell wall synthesis of susceptible bacteria.  <span class="Italics">In vitro</span>, piperacillin is active against a variety of Gram-positive and Gram-negative aerobic and anaerobic bacteria.  Tazobactam sodium has little clinically relevant <span class="Italics">in vitro </span>activity against bacteria due to its reduced affinity to penicillin-binding proteins. It is, however, a β-lactamase inhibitor of the Molecular class A enzymes, including Richmond-Sykes class III (Bush class 2b &amp; 2b') penicillinases and cephalosporinases.  It varies in its ability to inhibit class II and IV (2a &amp; 4) penicillinases.  Tazobactam does not induce chromosomally-mediated β-lactamases at tazobactam concentrations achieved with the recommended dosage regimen.</p>
<p>Spectrum of Activity</p>
<p>Piperacillin/tazobactam has been shown to be active against most isolates of the following microorganisms both <span class="Italics">in vitro </span>and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> [<span class="Italics">see Indications and Usage (<a href="#LINK_4c484783-2f41-4aff-bb25-60e1b183742c">1</a>)</span>].</p>
<p>Gram-positive bacteria:</p>
<p><span class="Italics">Staphylococcus aureus </span>(methicillin susceptible isolates only)</p>
<p>Gram-negative bacteria:<br><span class="Italics">Acinetobacter baumannii</span><br><span class="Italics">Escherichia coli</span><br><span class="Italics">Haemophilus influenzae </span>(excluding β-lactamase negative, ampicillin-resistant isolates)<br><span class="Italics">Klebsiella pneumoniae</span><br><span class="Italics">Pseudomonas aeruginosa </span>(given in combination with an aminoglycoside to which the isolate is susceptible)</p>
<p>Anaerobic bacteria:<br><span class="Italics">Bacteroides fragilis </span>group (<span class="Italics">B. fragilis, B. ovatus, B. thetaiotaomicron, </span>and <span class="Italics">B. vulgatus</span>)</p>
<p>The following <span class="Italics">in vitro </span>data are available, <span class="Bold">but their clinical significance is unknown</span>.</p>
<p>At least 90% of the following microorganisms exhibit an <span class="Italics">in vitro </span><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC) less than or equal to the susceptible breakpoint for piperacillin/tazobactam.  However, the safety and effectiveness of piperacillin/tazobactam in treating clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to these bacteria have not been established in adequate and well-controlled clinical trials. </p>
<p>Gram-positive bacteria:<br><span class="Italics">Enterococcus faecalis </span>(ampicillin or penicillin-susceptible isolates only) <span class="Italics">Staphylococcus epidermidis </span>(methicillin susceptible isolates only)<br><span class="Italics">Streptococcus agalactiae</span><span class="Sup">†</span><br><span class="Italics">Streptococcus pneumoniae</span><span class="Sup">† </span>(penicillin-susceptible isolates only)<br><span class="Italics">Streptococcus pyogenes</span><span class="Sup">† </span><br>Viridans group streptococci<span class="Sup">†</span></p>
<p>Gram-negative bacteria: <br><span class="Italics">Citrobacter koseri </span><br><span class="Italics">Moraxella catarrhalis </span><br><span class="Italics">Morganella morganii </span><br><span class="Italics">Neisseria gonorrhoeae </span><br><span class="Italics">Proteus mirabilis </span><br><span class="Italics">Proteus vulgaris </span><br><span class="Italics">Serratia marcescens </span><br><span class="Italics">Providencia stuartii </span><br><span class="Italics">Providencia rettgeri </span><br><span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> enterica </span></p>
<p>Anaerobic bacteria: <br><span class="Italics">Clostridium perfringens </span><br><span class="Italics">Bacteroides distasonis </span><br><span class="Italics">Prevotella melaninogenica </span></p>
<p><span class="Sup">†</span>These are not β-lactamase producing bacteria and, therefore, are susceptible to piperacillin alone.</p>
<p>Susceptibility Testing Methods</p>
<p>As is recommended with all antimicrobials, the results of <span class="Italics">in vitro </span>susceptibility tests, when available, should be provided to the physician as periodic reports, which describe the susceptibility profile of nosocomial and community-acquired pathogens.  These reports should aid the physician in selecting the most effective antimicrobial.</p>
<p><span class="Italics">Dilution Techniques:</span></p>
<p>Quantitative methods are used to determine antimicrobial <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentrations</span> (MICs).  These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds.  The MICs should be determined using a standardized procedure.  Standardized procedures are based on a dilution method (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of piperacillin and tazobactam powders.<span class="Sup">1,2</span>  MIC values should be determined using serial dilutions of piperacillin combined with a fixed concentration of 4 mcg/mL tazobactam.  The MIC values obtained should be interpreted according to criteria provided in Table 7.</p>
<p><span class="Italics">Diffusion Technique:</span></p>
<p>Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds.  The zone size provides an estimate of the susceptibility of bacteria to antimicrobial compounds.  The zone size should be determined using a standardized test method<span class="Sup">1,3</span> and requires the use of standardized inoculum concentrations.  This procedure uses paper disks impregnated with 100 mcg of piperacillin and 10 mcg of tazobactam to test the susceptibility of microorganisms to piperacillin/tazobactam.  The disk diffusion interpreted criteria are provided in Table 7.</p>
<p><span class="Italics">Anaerobic Techniques</span></p>
<p>For anaerobic bacteria, the susceptibility to piperacillin/tazobactam can be determined by the reference agar dilution method.<span class="Sup">4</span></p>
<table width="100%">
<col width="35%">
<col width="10%">
<col width="14%">
<col width="13%">
<col width="9%">
<col width="11%">
<col width="9%">
<tbody class="Headless">
<tr class="First"><td class="Toprule" align="center" colspan="7"><p class="First"><span class="Bold">Table 7:  Susceptibility Interpretive Criteria for Piperacillin/Tazobactam</span></p></td></tr>
<tr>
<td class="Botrule Rrule" align="center"><p class="First">   </p></td>
<td class="Botrule Lrule" align="center" colspan="6"><p class="First"><span class="Bold">Susceptibility Test Result Interpretive Criteria</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center"><p class="First">   </p></td>
<td class="Botrule Lrule Rrule" align="center" colspan="3"><p class="First">Minimal Inhibitory Concentration<br>(MIC in mcg/mL)</p></td>
<td class="Botrule Lrule" align="center" colspan="3" valign="bottom"><p class="First">Disk Diffusion<br>(Zone Diameter in mm)</p></td>
</tr>
<tr>
<td class="Botrule Rrule" align="center"><p class="First">Pathogen</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">S</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">I</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">R</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">S</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">I</p></td>
<td class="Botrule Lrule" align="center"><p class="First">R</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Italics">Enterobacteriaceae</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">≤ 16</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">32 – 64</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">≥ 128</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">≥ 21</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">18 – 20</p></td>
<td class="Botrule Lrule" align="center"><p class="First">≤ 17</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Italics">Acinetobacter baumannii</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">≤ 16</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">32 – 64</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">≥ 128</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">≥ 21</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">18 – 20</p></td>
<td class="Botrule Lrule" align="center"><p class="First">≤ 17</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Italics">Haemophilus influenzae<span class="Sup">a</span></span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">≤ 1</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">≥ 2</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">≥ 21</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Italics">Pseudomonas aeruginosa</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">≤ 16</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">32 – 64</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">≥ 128</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">≥ 21</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">15 – 20</p></td>
<td class="Botrule Lrule" align="center"><p class="First">≤ 14</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Italics">Bacteroides fragilis group</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">≤ 32</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">64 </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">≥ 128</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">-</p></td>
<td class="Botrule Lrule Rrule" align="center" valign="bottom"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-</p></td>
</tr>
<tr class="Last"><td class="Botrule" colspan="7"><p class="First"> <span class="Sup">a</span>These interpretive criteria for <span class="Italics">Haemophilus influenzae </span>are applicable only to tests performed using Haemophilus Test Medium inoculated with a direct colony suspension and incubated at 35°C in ambient air for 20 to 24 hours. Note:  Susceptibility of staphylococci to piperacillin/tazobactam may be deduced from testing only penicillin and either cefoxitin or oxacillin.</p></td></tr>
</tbody>
</table>
<p>A report of S (“Susceptible?) indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentration at the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> site necessary to inhibit growth of the pathogen.  A report of I (“Intermediate?) indicates that the results should be considered equivocal, and if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated.  This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used.  This category also provides a buffer zone, which prevents small, uncontrolled technical factors from causing major discrepancies in interpretation.  A report of R (“Resistant?) indicates that the pathogen is not likely to be inhibited even if the antimicrobial compound in the blood reaches the concentration usually achievable at the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> site; other therapy should be considered.</p>
<p><span class="Italics">Quality Control </span></p>
<p>Standardized susceptibility test procedures require the use of quality controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individuals performing the test procedures.<span class="Sup">1,2,3,4</span>  Standard piperacillin/tazobactam powder should provide the following ranges of values noted in Table 8<span class="Bold">.  </span>Quality control bacteria are specific <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of bacteria with intrinsic biological properties relating to resistance mechanisms and their genetic expression within the microorganism; the specific <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> used for microbiological quality control are not clinically significant.</p>
<table width="100%">
<col width="37%">
<col width="31%">
<col width="33%">
<tbody class="Headless">
<tr class="First"><td class="Botrule Toprule" align="center" colspan="3"><p class="First"><span class="Bold">Table 8:  Acceptable Quality Control Ranges for Piperacillin/Tazobactam</span><br><span class="Bold">to Be Used in Validation of Susceptibility Test</span></p></td></tr>
<tr>
<td><p class="First">     </p></td>
<td align="center" colspan="2"><p class="First"><span class="Bold">Acceptable Quality Control Ranges</span></p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">     </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Minimum Inhibitory</p></td>
<td class="Botrule Lrule" align="center"><p class="First">      </p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">     </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Concentration</p></td>
<td class="Botrule Lrule" align="center"><p class="First">Disk Diffusion</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">QC <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strain</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Range (MIC in mcg/mL)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">Zone Diameter Ranges in mm</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="bottom"><p class="First"><span class="Italics">Escherichia coli</span><br>ATCC 25922</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1 – 4</p></td>
<td class="Botrule Lrule" align="center"><p class="First">24 – 30</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="bottom"><p class="First"><span class="Italics">Escherichia coli </span><br>ATCC 35218 </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.5 – 2</p></td>
<td class="Botrule Lrule" align="center"><p class="First">24 – 30</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Italics">Pseudomonas aeruginosa </span><br>ATCC 27853 </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1 – 8</p></td>
<td class="Botrule Lrule" align="center"><p class="First">25 – 33</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Italics">Haemophilus influenzae</span><span class="Sup">a</span><br>ATCC 49247</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.06 – 0.5</p></td>
<td class="Botrule Lrule" align="center"><p class="First">33 – 38</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Italics">Staphylococcus aureus</span><br>ATCC 29213</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.25 – 2</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Italics">Staphylococcus aureus</span><br>ATCC 25923</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">-</p></td>
<td class="Botrule Lrule" align="center"><p class="First">27 – 36</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="bottom"><p class="First"><span class="Italics">Bacteroides fragilis</span><span class="Sup">b</span><br>ATCC 25285</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0.12 – 0.5</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Rrule" valign="bottom"><p class="First"><span class="Italics">Bacteroides thetaiotaomicron</span><span class="Sup">b</span><br>ATCC 29741</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4 – 16</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Italics">Clostridium difficile</span><span class="Sup">b</span><br><span class="Italics">ATCC 700057 </span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4 – 16</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Italics">Eubacterium lentum</span><span class="Sup">b</span><br><span class="Italics">ATCC 43055 </span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4 – 16</p></td>
<td class="Botrule Lrule" align="center"><p class="First">-</p></td>
</tr>
<tr class="Last"><td class="Botrule" colspan="3"><p class="First"><span class="Sup">a</span> This quality control range for <span class="Italics">Haemophilus influenzae </span>is applicable only to tests performed using Haemophilus Test Medium inoculated with a direct colony suspension and incubated at 35°C in ambient air for 20 to 24 hours.<br><span class="Sup">b</span> The quality control ranges for <span class="Italics">Bacteroides fragilis </span>and <span class="Italics">Bacteroides thetaiotaomicron </span>are applicable only to tests performed using the agar dilution method.</p></td></tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="LINK_1347059e-0b19-4951-978e-1ec79e765e17"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_5d9c9bae-e116-497b-ac61-eceb5d519709"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Long-term carcinogenicity studies in animals have not been conducted with piperacillin/tazobactam, piperacillin, or tazobactam.</p>
<p>Piperacillin/Tazobactam</p>
<p>Piperacillin/tazobactam was negative in microbial mutagenicity assays, the unscheduled DNA synthesis (UDS) test, a mammalian point mutation (Chinese hamster ovary cell HPRT) assay, and a mammalian cell (BALB/c-3T3) transformation assay.  <span class="Italics">In vivo</span>, piperacillin/tazobactam did not induce chromosomal aberrations in rats.</p>
<p><span class="Italics">Piperacillin/tazobactam</span></p>
<p>Reproduction studies have been performed in rats and have revealed no evidence of impaired fertility when piperacillin/tazobactam is administered intravenously up to a dose of 1280/320 mg/kg piperacillin/tazobactam, which is similar to the maximum recommended human daily dose based on body-surface area (mg/m<span class="Sup">2</span>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="LINK_4c672fce-8a59-4e82-ab64-287e1a0431bf"></a><a name="section-13"></a><p></p>
<h1>15 REFERENCES</h1>
<dl>
<dt>1.</dt>
<dd>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Performance Standards for Antimicrobial Susceptibility Testing; Twenty-third Informational Supplement</span>. CLSI document M100-S23, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2013.</dd>
<dt>2.</dt>
<dd>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard – Ninth Edition</span>. CLSI document M07-A9, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2012.</dd>
<dt>3.</dt>
<dd>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Performance Standards for Antimicrobial Disk Diffusion Susceptibility Tests; Approved Standard – Eleventh Edition.  </span>CLSI document M02-A11, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2012.</dd>
<dt>4.</dt>
<dd>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Approved Standard – Eight Edition</span>. CLSI document M11-A8. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, PA 19087 USA, 2012.</dd>
</dl>
<p class="First">CLINITEST<span class="Sup">®</span>is a registered trademark of Siemens Healthcare Diagnostics Inc.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_cf9b015e-3f82-4242-ba30-6fc80a47a4e2"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">Piperacillin and Tazobactam for Injection is supplied in the following size:</p>
<dl>
<dt>•</dt>
<dd>Each Piperacillin and Tazobactam for Injection 40.5 g pharmacy bulk package bottle provides piperacillin sodium equivalent to 36 grams of piperacillin and tazobactam sodium equivalent to 4.5 g of tazobactam.  Each pharmacy bulk package bottle contains 84.6 mEq (1945 mg) of sodium.</dd>
</dl>
<p>Product Code NP304074, NDC 63323-304-78</p>
<p>Piperacillin and Tazobactam for Injection pharmacy bulk package bottles should be stored at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature] prior to reconstitution.</p>
<p>This container closure is not made with natural rubber latex.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_f6ad6fb8-cd7b-4bb6-ad6d-617ebc2d615d"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Patients should be counseled that antibacterial drugs including piperacillin and tazobactam for injection should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>.  They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>).  When piperacillin and tazobactam for injection is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed.  Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by piperacillin and tazobactam for injection or other antibacterial drugs in the future.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibacterial drugs which usually ends when the drug is discontinued.  Sometimes after starting treatment with antibacterial drugs, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the drug.  If this occurs, patients should contact their physician as soon as possible.</p>
<p>For all questions concerning adverse reactions associated with the use of this product or for inquiries concerning our products, please contact us at 1-800-551-7176 or <a href="http://www.fresenius-kabi.us">www.fresenius-kabi.us</a>.</p>
<p>NOVAPLUS is a registered trademark of Novation, LLC.</p>
<p>Manufactured for:<br><span class="Bold">Fresenius Kabi USA, LLC</span></p>
<p>Lake Zurich, IL 60047            Made in Italy<br>451443                                 855993/Issued:  April 2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_7a4379b6-5684-49c5-96e6-bf035619dedc"></a><a name="section-16"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">Piperacillin and Tazobactam 40.5 grams per Pharmacy Bulk Package Bottle Label </span><br><span class="Bold">NDC 63323-304-78</span><br><span class="Bold">855992</span><br><span class="Bold">PIPERACILLIN AND TAZOBACTAM FOR INJECTION </span><br><span class="Bold">Pharmacy Bulk Package- Not for Direct Infusion </span><br><span class="Bold">Reconstituted stock solution must be transferred and further diluted for IV infusion. </span><br><span class="Bold">40.5 grams per Pharmacy Bulk Package </span><br><span class="Bold">For Intravenous Use Only</span><br><span class="Bold">Rx only</span></p>
<div class="Figure">
<a name="id2003"></a><img alt="NP PIP TAZ 40.5 vial label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=e53ebafc-3afa-4a1e-9313-fecd1c1c5d7c&amp;name=piperacillin-and-tazobactam-for-injection-anda-090-3.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PIPERACILLIN AND TAZOBACTAM 		
					</strong><br><span class="contentTableReg">piperacillin sodium and tazobactam sodium injection, powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63323-304</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PIPERACILLIN SODIUM</strong> (PIPERACILLIN ANHYDROUS) </td>
<td class="formItem">PIPERACILLIN ANHYDROUS</td>
<td class="formItem">36 g  in 180 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>TAZOBACTAM SODIUM</strong> (TAZOBACTAM) </td>
<td class="formItem">TAZOBACTAM</td>
<td class="formItem">4.5 g  in 180 mL</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63323-304-78</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">180 mL in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA090498</td>
<td class="formItem">05/31/2011</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Fresenius Kabi USA, LLC
							(608775388)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Istituto Biochimico Italiano Giovanni Lorenzini SpA</td>
<td class="formItem"></td>
<td class="formItem">432432581</td>
<td class="formItem">MANUFACTURE(63323-304)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>e53ebafc-3afa-4a1e-9313-fecd1c1c5d7c</div>
<div>Set id: e53ebafc-3afa-4a1e-9313-fecd1c1c5d7c</div>
<div>Version: 1</div>
<div>Effective Time: 20150612</div>
</div>
</div> <div class="DistributorName">Fresenius Kabi USA, LLC</div></p>
</body></html>
